Cost-Effectiveness of Antibiotics for Geriatric Pneumonia in an Indonesian Regional Hospital
Abstract
Cost-effectiveness of commonly used antibiotic regimens in geriatric inpatients with pneumonia was evaluated through a retrospective review of medical records at Pelabuhan Ratu Regional General Hospital (January–December 2021). Eligible patients were aged ≥60 years with a length of stay ≥2 days; 100 of 700 records met inclusion. Direct medical costs—antibiotics, inpatient care, and other medications—were obtained from hospital tariffs and expressed in Indonesian Rupiah (Rp). Clinical effectiveness at discharge was defined as temperature ≤37,8 °C, respiratory rate 30/min, and leukocyte count ≤10.500/µL. The most frequently used single agents were ceftriaxone (32%), levofloxacin (26%), azithromycin (14%), and cefixime (2%); common substitutions included ceftriaxone–azithromycin (9%) and levofloxacin–ceftriaxone (6%). The lowest average cost-effectiveness ratio (ACER) occurred with cefixime (Rp 581.209). In incremental analysis, levofloxacin–cefixime compared with ceftriaxone monotherapy yielded an incremental cost-effectiveness ratio (ICER) of Rp 117.786 per 1% additional effectiveness, supporting ceftriaxone as the more cost-effective option. Overall, cefixime was most economical by ACER, whereas ceftriaxone monotherapy was preferred by ICER.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.